Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study

Clinical Rheumatology

Volumn 34, Issue 10, 2015, Pages 1781-1785

  Brenol, Claiton Viegas ^a   da Chakr, Rafael Mendonça Silva ^a   Andrade, Nicole Pamplona Bueno ^a   Toni, Mariana ^a   Laurindo, Ieda Maria Magalhães ^b   Brenol, João Carlos Tavares ^a   Xavier, Ricardo Machado ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cohort; Effectiveness; Feasibility; Rheumatoid arthritis; Synthetic DMARDs; Treat to target

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL FEATURE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VISUAL ANALOG SCALE; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; FEASIBILITY STUDY; INFLAMMATION; MIDDLE AGED; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TREATMENT OUTCOME;

EID: 84942297016     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-2915-0     Document Type: Article

References (28)

1. van Tuyl LH et al (2008) Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90 % remission in a pilot trial. Ann Rheum Dis 67(11):1574–7
2. Verstappen SM et al (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66(11):1443–9
3. Grigor C et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430):263–9
4. Fransen J et al (2005) Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 64(9):1294–8
5. Goekoop-Ruiterman YP et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52(11):3381–90
6. Hetland ML et al (2008) Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 67(6):815–22
7. Saunders SA et al (2008) Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 58(5):1310–7
8. Verschueren P, Esselens G, Westhovens R (2008) Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 47(1):59–64
9. Moreland LW et al (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 64(9):2824–35
10. Schipper LG et al (2011) A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch rheumatoid arthritis monitoring registry. Ann Rheum Dis 71(6):845–50
11. Mottonen T et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353(9164):1568–73
12. Jurgens MS, Welsing PM, Jacobs JW (2012) Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission. Clin Exp Rheumatol 30(4 Suppl 73):S56–63
13. Pincus T, Castrejon I (2013) Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis 71(Suppl 1):S33–40
14. Smolen JS et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964–75
15. Sokka T, Pincus T (2009) Rheumatoid arthritis: strategy more important than agent. Lancet 374(9688):430–2
16. Bakker MF et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156(5):329–39
17. Montecucco C et al (2012) Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 14(3):R112
18. Ling E et al (2013) Outcome of patients with rheumatoid arthritis: cross-sectional study of a single-center real-world inception cohort. Isr Med Assoc J 15(12):758–62
19. Buch MH et al (2013) Creative trial design in RA: optimizing patient outcomes. Nat Rev Rheumatol 9(3):183–94
20. Arnett FC et al (1988) The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–24
21. Maska L, Anderson J, Michaud K (2012) Measures of functional status and quality of life in rheumatoid arthritis: health assessment questionnaire disability index (HAQ), modified health assessment questionnaire (MHAQ), multidimensional health assessment questionnaire (MDHAQ), health assessment questionnaire II (HAQ-II), improved health assessment questionnaire (improved HAQ), and rheumatoid arthritis quality of life (RAQoL). Arthritis Care Res (Hoboken) 63(Suppl 11):S4–13
22. Anderson JK et al (2011) Measures of rheumatoid arthritis disease activity: patient (PtGA) and provider (PrGA) global assessment of disease activity, disease activity score (DAS) and disease activity score with 28-joint counts (DAS28), simplified disease activity index (SDAI), clinical disease activity index (CDAI), patient activity score (PAS) and patient activity score-II (PASII), routine assessment of patient index data (RAPID), rheumatoid arthritis disease activity index (RADAI) and rheumatoid arthritis disease activity index-5 (RADAI-5), chronic arthritis systemic index (CASI), patient-based disease activity score with ESR (PDAS1) and patient-based disease activity score without ESR (PDAS2), and mean overall index for rheumatoid arthritis (MOI-RA). Arthritis Care Res (Hoboken) 63(Suppl 11):S14–36
23. Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43(10):1252–5
24. Aletaha D et al (2005) Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 52(9):2625–36
25. Sokka T et al (2008) Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 58(9):2642–51
26. Dale J et al (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res (Hoboken) 66(1):19–26
27. Colebatch AN et al (2013) EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 72(6):804–14
28. Santos-Moreno PI et al (2015) Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. Clin Rheumatol 34(2):215–20